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1. INTRODUCTION {#cas14309-sec-0001}
===============

Cancer is the second leading cause of death worldwide, with an estimated 9.6 million lives lost in 2018.[1](#cas14309-bib-0001){ref-type="ref"} Following the diagnosis of cancer, receiving treatment at a "good" hospital would be a critical issue for patients because cancer is a life‐threatening disease. Since the effect of surgery volumes on mortality was reported in the United States in 1979,[2](#cas14309-bib-0002){ref-type="ref"} several studies have accumulated evidence on the volume‐outcome relationship; patients undergoing treatment at high‐volume hospitals have better outcomes compared to those treated at low‐volume hospitals.[3](#cas14309-bib-0003){ref-type="ref"}, [4](#cas14309-bib-0004){ref-type="ref"} A potential mechanism of the volume‐outcome relationship is that hospitals with greater case volumes are likely to be equipped with skilled resources and advanced medical infrastructure, thereby providing optimal treatment and care; consequently, their patients obtain better treatment outcomes.[5](#cas14309-bib-0005){ref-type="ref"}

Hospital volumes have been measured according to various definitions, including the number of patients who were diagnosed, received treatment[5](#cas14309-bib-0005){ref-type="ref"}, [6](#cas14309-bib-0006){ref-type="ref"}, [7](#cas14309-bib-0007){ref-type="ref"}, [8](#cas14309-bib-0008){ref-type="ref"} or underwent surgeries.[4](#cas14309-bib-0004){ref-type="ref"} Surgical procedure volume is a commonly used measurement to assess the volume‐outcome relationship.[4](#cas14309-bib-0004){ref-type="ref"} To date, there is no gold standard for the thresholds of hospital volume. As an alternative, studies have categorized hospital volume by percentiles,[9](#cas14309-bib-0009){ref-type="ref"}, [10](#cas14309-bib-0010){ref-type="ref"}, [11](#cas14309-bib-0011){ref-type="ref"}, [12](#cas14309-bib-0012){ref-type="ref"} clinically relevant cutoffs[13](#cas14309-bib-0013){ref-type="ref"}, [14](#cas14309-bib-0014){ref-type="ref"} or convenient cutoffs.[15](#cas14309-bib-0015){ref-type="ref"}, [16](#cas14309-bib-0016){ref-type="ref"}, [17](#cas14309-bib-0017){ref-type="ref"} This heterogeneity of surgical volume measurements may affect the external validity of study results.[4](#cas14309-bib-0004){ref-type="ref"} Patient outcomes used in previous studies have also varied; these include 5‐year survival,[7](#cas14309-bib-0007){ref-type="ref"}, [18](#cas14309-bib-0018){ref-type="ref"} postoperative mortality,[19](#cas14309-bib-0019){ref-type="ref"}, [20](#cas14309-bib-0020){ref-type="ref"} procedure‐related complications[11](#cas14309-bib-0011){ref-type="ref"}, [21](#cas14309-bib-0021){ref-type="ref"} and recurrence of cancer.[16](#cas14309-bib-0016){ref-type="ref"}, [22](#cas14309-bib-0022){ref-type="ref"} Although a number of studies have demonstrated that patients treated at high‐volume hospitals have better outcomes, patient characteristics are critical confounders to the choice of hospital and patient outcomes.[23](#cas14309-bib-0023){ref-type="ref"}, [24](#cas14309-bib-0024){ref-type="ref"} In addition, the variation of volume‐outcome relationships may be affected by the clinical rarity and technical complexity of the surgical procedure. For instance, rare, complex cancer operations have stronger associations with mortality than common and simple operations.[25](#cas14309-bib-0025){ref-type="ref"}

Although the strength of the association between hospital volume and mortality varies according to the type of surgery,[25](#cas14309-bib-0025){ref-type="ref"} some countries have applied the evidence of volume‐outcome relationships to quality and safety control programs. For instance, state authorities or professional societies in European and North American countries assess whether hospitals meet minimum volume standards for pancreatic, esophageal, lung, hepatic or biliary tract resections, and levy penalties or offer interventions to non--compliant hospitals.[26](#cas14309-bib-0026){ref-type="ref"} In the United States, the National Cancer Policy Board recommends surgery volume as a quality indicator,[3](#cas14309-bib-0003){ref-type="ref"}, [27](#cas14309-bib-0027){ref-type="ref"} and a non--profit organization conducts hospital surveys and presents the achievement status of minimal surgical volume to individual hospitals.[28](#cas14309-bib-0028){ref-type="ref"}

In Japan, a minimum hospital volume standard is used as an eligibility criterion for designated cancer care hospitals, and as an indicator to monitor their performance.[29](#cas14309-bib-0029){ref-type="ref"} The majority of studies on the volume‐outcome relationship previously conducted in Japan focused on a single cancer site.[21](#cas14309-bib-0021){ref-type="ref"}, [30](#cas14309-bib-0030){ref-type="ref"}, [31](#cas14309-bib-0031){ref-type="ref"}, [32](#cas14309-bib-0032){ref-type="ref"}, [33](#cas14309-bib-0033){ref-type="ref"}, [34](#cas14309-bib-0034){ref-type="ref"}, [35](#cas14309-bib-0035){ref-type="ref"} One study reported the volume‐survival relationship for multiple sites of cancer diagnosed in 1994‐1998; hospital volume was defined by the number of patients treated.[7](#cas14309-bib-0007){ref-type="ref"} Since then, Osaka has changed in terms of its population structure, medical technology and cancer control policy, and has improved its cancer registry system. Moreover, patients undergo surgeries or non--surgical treatments in real‐world settings. Surgical indications are influenced by the preoperative functional ability and are predictive of prognosis. Therefore, focusing on surgical cases is likely to illustrate the volume‐outcome association more clearly than cases undergoing treatment by all modalities. Updated evidence in a sample of patients undergoing surgeries is therefore needed. This study examined the association between surgery‐based hospital procedure volumes and survival of cancer patients between 2007 and 2011.

2. MATERIALS AND METHODS {#cas14309-sec-0002}
========================

2.1. Study design, setting and data source retrieved {#cas14309-sec-0003}
----------------------------------------------------

This retrospective cohort study used individual data of cancer patients from the Osaka Cancer Registry (OCR). The OCR is a population‐based longitudinal database that registers all cancer cases and follows up their vital status in Osaka Prefecture, Japan. An estimated population of 8.9 million resided in Osaka according to the 2010 census.[36](#cas14309-bib-0036){ref-type="ref"} Since the registry system was introduced in 1962, the OCR has been collecting data on new cancer cases from medical facilities and the prefectural administration. The database includes individual information on sex, age, date of diagnosis and death, cancer sites defined by the International Classification of Diseases 10th edition (ICD‐10), cancer stage, treatment type (ie, surgery, adjuvant therapy and radiation therapy), medical facilities utilized at the first contact, diagnosis and primary treatment. The database does not have information on socioeconomic characteristics of individuals, their comorbidity status, functional ability or details of treatment (eg the period of treatment or any treatment undergone for cancer or other diseases after the primary treatment). Although the database does not have information on the social health insurance status of individuals, nearly the entire population in Japan is insured, and the contents and the fees for medical and health services covered by the insurance scheme are fixed across medical facilities.[37](#cas14309-bib-0037){ref-type="ref"} The OCR updates the vital status of all registered cases at 3, 5 and 10 years from diagnosis. The proportion of incident cases in the database notified only by death certificates in 2011 was 8.7%, and the incidence/mortality ratio was 2.24.[38](#cas14309-bib-0038){ref-type="ref"}

2.2. Study sample {#cas14309-sec-0004}
-----------------

Cancer cases of the following five sites were analyzed: stomach (C16 in ICD‐10), colorectum (C18, C19, and C20), lung (C33 and C34), breast (C50) and uterus (C53, C54 and C55). We selected these cancer sites as they accounted for 55.5% of the overall cancer incidence during the study period. The study sample met the following criteria: diagnosed with cancer between 2007 and 2011, lived in Osaka at the time of diagnosis, aged 15‐99 years at diagnosis, and had undergone surgery at hospitals in Osaka. We excluded those who underwent surgery at clinics or those whose deaths were exclusively notified by death certificates. The remainder were included in the study sample for generating variables for hospital volume. For survival analysis, we excluded those aged 85‐99 years as older age is a critical confounder to the choice of hospital[23](#cas14309-bib-0023){ref-type="ref"}, [24](#cas14309-bib-0024){ref-type="ref"} and survival probability. Male breast cancer cases and cases where there was a lack of information regarding the survival status at 5 years from diagnosis or the survival period between the diagnosis and the last observation were excluded from the analysis (Figure [1](#cas14309-fig-0001){ref-type="fig"}).

![Flowchart of the study sample selection](CAS-111-985-g001){#cas14309-fig-0001}

2.3. Potential confounders {#cas14309-sec-0005}
--------------------------

The following variables were used as potential confounders: year of diagnosis (2007, 2008, 2009, 2010 and 2011), sex (men and women), age group (15‐54, 55‐64, 65‐74 and 75‐84), stage of cancer (localized \[cancer remained in the initial organ\], regional \[cancer spread to regional lymph nodes or adjacent tissues\], distant \[cancer spread to distant organs\] and unknown), extent of resection of primary tumor (all, partial and unknown), receipt of adjuvant therapy (received, not received and unknown), receipt of radiation therapy (received, not received and unknown) and residential area (eight divisions according to the prefectural medical administration system).

2.4. Study outcome {#cas14309-sec-0006}
------------------

The primary outcome of this study was the 5‐year survival from the time of cancer diagnosis. We terminated observations on the date of death that might have occurred any time within 5 years from diagnosis or were censored at 5 years from diagnosis, if participants survived.

2.5. Categorization of hospital volume {#cas14309-sec-0007}
--------------------------------------

We defined hospital volume as the annual average volume of surgeries undertaken by a hospital for each site of cancer. The surgical procedures referred to were open, endoscopic or laparoscopic resections performed on patients aged 15‐99 years. For categorization of hospital volumes, we calculated average annual surgery volumes during 2007‐2011, and ranked hospitals by their annual surgery volume. We then sorted patients in descending order of surgery volumes and assigned them into four equally sized groups (high‐volume, medium‐volume, low‐volume and very low‐volume hospitals).

2.6. Statistical analysis {#cas14309-sec-0008}
-------------------------

First, we calculated the number of hospitals, mean and the range of annual surgery volume, and the number of patients for each hospital volume category. We compared the distribution of the basic characteristics of the study sample among the five selected cancer sites. We then estimated the mortality hazard ratios of hospital volumes using the Cox proportional hazard regression model. In the model, we controlled potential confounders, including the year of diagnosis, sex, age group, cancer stage, extent of resection of primary tumor, receipt of adjuvant therapy, receipt of radiation therapy and residential area. We adjusted the confidence intervals of the hazard ratio using robust estimators of variance as the study sample within the same hospital would have cluster correlations. Finally, we estimated adjusted survival rates based on multivariable Cox proportional hazard regression. To provide further supporting information, we examined factors associated with surgery at very low‐volume hospitals (1 = very low‐volume hospitals, 0 = high‐volume, medium‐volume and low‐volume hospitals) using multivariable logistic regression. We defined statistical significance as a *P*‐value of \<0.05. The Stata 14.2 statistical software package was used for all analyses (Stata).

2.7. Ethical considerations {#cas14309-sec-0009}
---------------------------

We obtained ethical approval from the Institutional Review Board of Osaka International Cancer Institute (approval number: 18‐0018) before initiating the study. The data had been anonymized before use.

3. RESULTS {#cas14309-sec-0010}
==========

We identified 144 941 cases diagnosed with cancer at any of the five selected sites between 2007 and 2011, selected 86 145 cases for generating categorical variables for hospital volume, and identified 80 959 cases for survival analysis (Figure [1](#cas14309-fig-0001){ref-type="fig"}). After excluding ineligible samples, the number of study samples included in the analysis was: 24 567 for stomach cancer, 27 264 for colorectal cancer, 9095 for lung cancer, 15 287 for breast cancer and 4746 for uterine cancer. In comparison to the initial sample diagnosed with cancer at the selected sites, the sample who received surgery and met the criteria for analysis fell to 60.7% for stomach cancer, 69.4% for colorectal cancer, 24.9% for lung cancer, 71.2% for breast cancer and 66.4% for uterine cancer.

Table [1](#cas14309-tbl-0001){ref-type="table"} shows the hospital characteristics per hospital volume category. After assigning study samples to the hospital volume quartiles, the number of hospitals included in the analysis was 170 for stomach cancer, 183 for colorectal cancer, 105 for lung cancer, 120 for breast cancer and 69 for uterine cancer. Among them, the number of very low‐volume hospitals accounted for nearly 76.8%‐81.0% of all hospitals. The mean annual volume in the high‐volume hospitals was 197.1 for stomach, 169.6 for colorectal, 140.0 for lung, 154.8 for breast and 71.9 for uterine cancer, whereas in the very low‐volume hospitals the mean annual volume was 9.8 for stomach, 10.7 for colorectal, 5.5 for lung, 8.8 for breast and 4.8 for uterine cancer.

###### 

Distribution of hospitals and annual hospital volume by hospital volume category

                                  Stomach               Colorectum            Lung                  Breast                Uterus
  ------------------------------- --------------------- --------------------- --------------------- --------------------- ------------------
  Hospital: N (%)                 170 (100.0)           183 (100.0)           105 (100.0)           120 (100.0)           69 (100.0)
  High                            6 (3.5)               8 (4.4)               3 (2.9)               5 (4.2)               3 (4.3)
  Medium                          11 (6.5)              13 (7.1)              6 (5.7)               8 (6.7)               5 (7.2)
  Low                             18 (10.6)             20 (10.9)             11 (10.5)             13 (10.8)             8 (11.6)
  Very low                        135 (79.4)            142 (77.6)            85 (81.0)             94 (78.3)             53 (76.8)
  Hospital volume: mean (range)                                                                                           
  High                            197.1 (167.4‐228.8)   169.6 (141.2‐205.0)   140.0 (111.2‐164.2)   154.8 (112.6‐197.8)   71.9 (64.8‐84.6)
  Medium                          128.7 (98.6‐151.2)    119.5 (100.0‐139.0)   83.0 (68.0‐109.0)     95.8 (86.0‐108.0)     53.5 (45.4‐59.0)
  Low                             73.3 (57.8‐93.8)      73.8 (53.6‐94.6)      44.2 (31.2‐65.4)      66.4 (44.8‐80.6)      29.8 (19.4‐45.0)
  Very low                        9.8 (0.2‐50.6)        10.7 (0.2‐53.4)       5.5 (0.2‐26.0)        8.8 (0.2‐43.6)        4.8 (0.2‐17.4)
  Patients: N (%)                 24 567 (100.0)        27 264 (100.0)        9095 (100.0)          15 287 (100.0)        4746 (100.0)
  High                            5661 (23.0)           6400 (23.5)           2048 (22.5)           3760 (24.6)           1062 (22.4)
  Medium                          6167 (25.1)           6813 (25.0)           2422 (26.6)           3700 (24.2)           1309 (27.6)
  Low                             6582 (26.8)           7228 (26.5)           2205 (24.2)           3873 (25.3)           1154 (24.3)
  Very low                        6157 (25.1)           6823 (25.0)           2420 (26.6)           3954 (25.9)           1221 (25.7)

Annual hospital volume was calculated based on the average annual number of surgeries undergone by patients per hospital during 2007‐2011.
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Table [2](#cas14309-tbl-0002){ref-type="table"} shows the distribution of the study sample characteristics for each cancer site. Men accounted for a higher proportion than women, particularly in the case of stomach cancer (70.7%). Among the four age groups, the group aged 65‐74 years accounted for the highest proportion in stomach, colorectal and lung cancers, whereas the group aged 15‐54 years accounted for the highest proportion in breast and uterine cancers. Approximately 62%‐66% of the study sample was diagnosed with localized stage cancer, except for colorectal cancers (47%). Approximately 76%‐86% had undergone complete tumor resection. The distribution of the study sample characteristics per hospital volume category is presented in Tables [S1‐S5](#cas14309-sup-0001){ref-type="supplementary-material"}.

###### 

Basic characteristics of study sample

  Characteristics                        Stomach         Colorectum      Lung          Breast           Uterus
  -------------------------------------- --------------- --------------- ------------- ---------------- --------------
  Years of diagnosis                                                                                    
  2007                                   4619 (18.8)     5198 (19.1)     1672 (18.4)   2963 (19.4)      866 (18.2)
  2008                                   4549 (18.5)     4927 (18.1)     1611 (17.7)   2843 (18.6)      790 (16.6)
  2009                                   4845 (19.7)     5301 (19.4)     1711 (18.8)   2840 (18.6)      867 (18.3)
  2010                                   5100 (20.8)     5717 (21.0)     1940 (21.3)   3295 (21.6)      1073 (22.6)
  2011                                   5454 (22.2)     6121 (22.5)     2161 (23.8)   3346 (21.9)      1150 (24.2)
  Sex                                                                                                   
  Men                                    17 369 (70.7)   16 341 (59.9)   5829 (64.1)   --               --
  Women                                  7198 (29.3)     10 923 (40.1)   3266 (35.9)   15 287 (100.0)   4746 (100.0)
  Age group                                                                                             
  15‐54                                  2022 (8.2)      2597 (9.5)      671 (7.4)     5700 (37.3)      2132 (44.9)
  55‐64                                  5758 (23.4)     6737 (24.7)     2289 (25.2)   4228 (27.7)      1464 (30.8)
  65‐74                                  9621 (39.2)     10 358 (38.0)   3833 (42.1)   3492 (22.8)      838 (17.7)
  75‐84                                  7166 (29.2)     7572 (27.8)     2302 (25.3)   1867 (12.2)      312 (6.6)
  Cancer stage                                                                                          
  Localized                              15 347 (62.5)   12 892 (47.3)   5702 (62.7)   10 074 (65.9)    3071 (64.7)
  Regional                               6320 (25.7)     9256 (33.9)     2660 (29.2)   4665 (30.5)      1325 (27.9)
  Distant                                2501 (10.2)     4569 (16.8)     566 (6.2)     275 (1.8)        230 (4.8)
  Unknown                                399 (1.6)       547 (2.0)       167 (1.8)     273 (1.8)        120 (2.5)
  Extent of resection of primary tumor                                                                  
  All                                    19 486 (79.3)   21 288 (78.1)   6910 (76.0)   13 117 (85.8)    3817 (80.4)
  Partial                                3320 (13.5)     4125 (15.1)     1459 (16.0)   1280 (8.4)       533 (11.2)
  Unknown                                1761 (7.2)      1851 (6.8)      726 (8.0)     890 (5.8)        396 (8.3)
  Adjuvant therapy                                                                                      
  Yes                                    5733 (23.3)     9511 (34.9)     2589 (28.5)   10 796 (70.6)    1977 (41.7)
  No                                     18 325 (74.6)   17 145 (62.9)   6316 (69.4)   4145 (27.1)      2695 (56.8)
  Unknown                                509 (2.1)       608 (2.2)       190 (2.1)     346 (2.3)        74 (1.6)
  Radiation therapy                                                                                     
  Yes                                    73 (0.3)        484 (1.8)       516 (5.7)     5499 (36.0)      597 (12.6)
  No                                     24 016 (97.8)   26 234 (96.2)   8405 (92.4)   9618 (62.9)      4055 (85.4)
  Unknown                                478 (1.9)       546 (2.0)       174 (1.9)     170 (1.1)        94 (2.0)
  Residential area                                                                                      
  Area A                                 7380 (30.0)     8796 (32.3)     2736 (30.1)   4474 (29.3)      1375 (29.0)
  Area B                                 2710 (11.0)     3163 (11.6)     869 (9.6)     1865 (12.2)      543 (11.4)
  Area C                                 2168 (8.8)      2286 (8.4)      942 (10.4)    1281 (8.4)       380 (8.0)
  Area D                                 2765 (11.3)     2574 (9.4)      983 (10.8)    1594 (10.4)      578 (12.2)
  Area E                                 2365 (9.6)      2854 (10.5)     882 (9.7)     1504 (9.8)       475 (10.0)
  Area F                                 1934 (7.9)      1996 (7.3)      778 (8.6)     1170 (7.7)       418 (8.8)
  Area G                                 2462 (10.0)     2886 (10.6)     1031 (11.3)   1672 (10.9)      515 (10.9)
  Area H                                 2783 (11.3)     2709 (9.9)      874 (9.6)     1727 (11.3)      462 (9.7)
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Table [3](#cas14309-tbl-0003){ref-type="table"} shows the mortality hazards per hospital volume category per cancer site. For each cancer site, the very low‐volume hospitals showed significantly higher mortality hazards than the high‐volume hospitals, after controlling for the potential confounders: 1.82 (95% CI: 1.54‐2.17) in stomach cancers, 1.57 (95% CI: 1.36‐1.81) in colorectal cancers, 1.49 (95% CI: 1.09‐2.04) in lung cancers, 1.39 (95% CI: 1.17‐1.64) in breast cancers, and 1.36 (95% CI: 1.13‐1.64) in uterine cancers. The low‐volume hospitals also presented higher mortality hazards than the high‐volume hospitals at two sites: 1.30 (95% CI: 1.10‐1.53) for stomach cancers and 1.16 (95% CI: 1.02‐1.31) for colorectal cancers. The hazard ratios of the other variables are presented in Table [S6](#cas14309-sup-0001){ref-type="supplementary-material"}. Patients who were male, of older age and had regional/distant stages of cancer at diagnosis (except colorectal and uterine cancers) were more likely to undergo surgery at very low‐volume hospitals (Table [S7](#cas14309-sup-0001){ref-type="supplementary-material"}).

###### 

Mortality hazards by multivariable Cox proportional hazard regression

                Stomach   Colorectum   Lung   Breast      Uterus                                         
  ------------- --------- ------------ ------ ----------- -------- ----------- ------ ----------- ------ -----------
  Crude HR                                                                                               
  High          1.00                   1.00               1.00                 1.00               1.00    
  Medium        1.17      0.93‐1.47    1.08   0.93‐1.25   1.17     0.83‐1.65   1.18   0.98‐1.42   0.97   0.82‐1.15
  Low           1.39      1.11‐1.73    1.20   1.04‐1.39   1.11     0.81‐1.52   1.29   1.06‐1.56   1.15   1.05‐1.24
  Very low      2.29      1.81‐2.91    1.76   1.49‐2.07   1.70     1.23‐2.36   1.75   1.43‐2.12   1.19   1.00‐1.41
  Adjusted HR                                                                                            
  High          1.00                   1.00               1.00                 1.00               1.00    
  Medium        1.14      0.95‐1.36    1.08   0.94‐1.24   1.20     0.87‐1.67   1.09   0.91‐1.30   1.10   0.89‐1.35
  Low           1.30      1.10‐1.53    1.16   1.02‐1.31   1.03     0.75‐1.42   1.10   0.92‐1.31   1.15   1.00‐1.32
  Very low      1.82      1.54‐2.17    1.57   1.36‐1.81   1.49     1.09‐2.04   1.39   1.17‐1.64   1.36   1.13‐1.64

Adjusted hazard ratios were controlled for year of diagnosis, sex, age group, cancer stage, extent of resection of primary tumor, adjuvant therapy received, radiation therapy received and residential area (The full result is reported in Table [S6](#cas14309-sup-0001){ref-type="supplementary-material"}).

Abbreviations: CI, confidence interval; High, high‐volume hospitals; HR, hazard ratio; Low, low‐volume hospitals; Medium, medium‐volume hospitals; Very low, very low‐volume hospitals.
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Figure [2](#cas14309-fig-0002){ref-type="fig"} shows plots of the adjusted 5‐year survival rates per hospital volume category. The adjusted 5‐year survival rates in high‐volume hospitals were 77.1% for stomach cancers, 74.5% for colorectal cancers, 71.8% for lung cancers, 93.4% for breast cancers and 90.0% for uterine cancers. The adjusted 5‐year survival rates in very low‐volume hospitals were 62.2% in stomach cancers, 63.0% in colorectal cancers, 61.0% in lung cancers, 91.0% in breast cancers and 86.7% in uterine cancers. Thus, the absolute difference (percentage points) in the adjusted 5‐year survival rates between high‐volume and very low‐volume hospitals was 14.9 in stomach cancers, 11.5 in colorectal cancers, 10.8 in lung cancers, 2.4 in breast cancers and 3.3 in uterine cancers. The Kaplan‐Meier survival curve and the adjusted survival curve of the Cox proportional hazards model are presented in Figures [S1‐S5](#cas14309-sup-0001){ref-type="supplementary-material"}.

![Adjusted 5‐y survival rates per hospital volume category based on post--estimations of multivariable Cox proportional hazard regression. High, high‐volume hospitals; Low, low‐volume hospitals; Medium, medium‐volume hospitals; Very low, very low‐volume hospitals](CAS-111-985-g002){#cas14309-fig-0002}

4. DISCUSSION {#cas14309-sec-0011}
=============

Patients treated at very low‐volume hospitals showed a significantly higher mortality hazard than those treated at high‐volume hospitals across the five selected sites of cancer. However, the strength of the volume‐survival relationship varied with the cancer site. The differences in survival probability between very low‐volume and low‐volume hospitals were greater than those among low‐volume, medium‐volume and high‐volume hospitals. Overall, the results were consistent with those of a previous study conducted at the same study site.[7](#cas14309-bib-0007){ref-type="ref"} Factors associated with undergoing surgery at very low‐volume hospitals were male gender, older age and regional/distant stage at cancer diagnosis.

The absolute differences in survival rates between high‐volume and very low‐volume hospitals were relatively large in stomach, colorectal and lung cancers (10‐15 percentage point difference) compared to breast and uterine cancers (2‐3 percentage point difference). This highlights that the strength of the volume‐survival relationship varied with the cancer site. Such variations with cancer sites suggest that the surgery volume standard should be defined by the cancer site or surgery type, and the application of a minimum volume standard would be beneficial for improving patient survival, particularly in surgeries for cancer with a strong volume‐survival relationship. Based on this idea, many countries have adopted minimum surgery volumes per cancer site; however, their thresholds vary. For instance, the minimum surgery volume for lung cancer is 50 cases in Canada and 20 in the Netherlands.[26](#cas14309-bib-0026){ref-type="ref"} This suggests that volume standards should be formulated based on country‐specific characteristics, such as the burden of cancer and healthcare systems.

Moreover, the plots of adjusted survival rates per hospital volume category showed a wider interval between very low‐volume and low‐volume hospitals, whereas narrower intervals were observed among low‐volume, medium‐volume and high‐volume hospitals. The findings have two implications. First, a hospital with a lack of surgical experience may negatively affect patient survival. This supports the idea that applying a minimum hospital volume standard, is advantageous. Second, patient survival may not be affected by the hospital volume if hospitals perform a greater number of surgical procedures than the minimum volume threshold. Because the site of the study was an urban area with the third largest population in the country, the hospitals with low‐volume or medium‐volume may have had frequent opportunities to perform surgeries[32](#cas14309-bib-0032){ref-type="ref"}, [33](#cas14309-bib-0033){ref-type="ref"} compared to rural areas. Thus, hospitals with very low surgery volumes should proactively refer their patients to higher volume hospitals. The performance of hospitals with very low surgery volumes should be carefully monitored to raise the standard of surgeries across hospitals in the study area.

The volume‐survival relationship observed in this study was generally consistent with that of a previous study conducted in Osaka in 1994‐1998[7](#cas14309-bib-0007){ref-type="ref"}; the lower volume hospitals showed higher mortality hazards. However, the hazard ratios of medium‐volume and low‐volume hospitals relative to high‐volume hospitals were not necessarily comparable. Definitions of hospital volume may have been responsible for the difference; we used surgery volume as the definition, whereas the previous study used treatment volumes, including surgery, radiotherapy, chemotherapy and others; those who did not undergo surgery were also included. We used surgery‐based hospital volumes as having undergone surgery implies that the patient had sufficient prior functional ability needed to tolerate surgical damage; this could be a confounder to patient survival. Despite such differences, our study updated the evidence on the volume‐survival relationship at the study site. A future analysis with a restricted sample not receiving surgery may be worthwhile.

This study has several limitations. First, the relationship between hospital volumes and patient survival does not explain causality. Second, the lack of individual information, such as socioeconomic characteristics, comorbidity and functional status may have affected the relevance of the study results. Lack of information on hospital characteristics was another limitation as patient volume per surgeon, patient‐surgery ratio or the availability of expert surgeons could affect patient outcomes. Furthermore, we could not control time‐varying factors, such as the introduction of a new drug or technology, transfer of patients to other hospitals after the primary treatment or experience with other diseases that may affect patient survival.

In conclusion, patients treated at low‐volume hospitals were at higher risk of mortality from five cancers. Monitoring hospital volumes and promoting referral of patients from very low‐volume hospitals to specialized hospitals would be beneficial for improving the survival of cancer patients. Furthermore, minimum surgery volume standards per cancer site are worth exploring in future research, and the application of the standards would potentially improve long‐term survival among cancer patients in Japan.
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